GILEAD SCIENCES, INC. (GILD)
Gilead Sciences, Inc. (NASDAQ: GILD) is a global biopharmaceutical company headquartered in Foster City, California. It develops and commercializes medicines for HIV, viral hepatitis, cancer, and inflammatory diseases. Its portfolio includes antiviral therapies, oncology treatments, and cell therapies through its subsidiary Kite Pharma. Gilead also invests heavily in research and development, with a focus on long-acting HIV prevention, innovative cancer treatments, and next-generation medicines.
| Ticker | GILD |
|---|
| Company | GILEAD SCIENCES, INC. |
|---|
| Exchange | Nasdaq |
|---|
| Headquarters | FOSTER CITY, CA |
|---|
Income statement — period ending 2026-06-30
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$10,479,000,000 |
|---|
| Cost of Goods and Services Sold | $1,579,000,000 |
|---|
| Earnings Per Share, Basic | -8 USD/shares |
|---|
| Earnings Per Share, Diluted | -8 USD/shares |
|---|
| Gross Profit (derived) | $6,224,000,000 |
|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | -$10,254,000,000 |
|---|
| Income Tax Expense (Benefit) | $242,000,000 |
|---|
| InterestExpenseNonoperating | $247,000,000 |
|---|
| Net Income (Loss) Attributable to Parent | -$10,496,000,000 |
|---|
| Nonoperating Income (Expense) | $387,000,000 |
|---|
| Operating Income (Loss) | -$10,394,000,000 |
|---|
| Other Nonoperating Income (Expense) | -$1,000,000 |
|---|
| Restructuring Charges | $17,000,000 |
|---|
| Revenue from Contract with Customer, Excluding Assessed Tax | $7,803,000,000 |
|---|
| Selling, General and Administrative Expense | $1,921,000,000 |
|---|
| Share-based Payment Arrangement, Noncash Expense | $449,000,000 |
|---|
| Weighted Average Number of Shares Outstanding, Diluted | 1,243,000,000 shares |
|---|
| Weighted Average Number of Shares Outstanding, Basic | 1,243,000,000 shares |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro